<DOC>
	<DOCNO>NCT01091740</DOCNO>
	<brief_summary>This study try 1 ) evaluate neointimal coverage malapposition 3 month new zotarolimus elute stent ( Endeavor resolute ) everolimus elute stent ( Xience ) implantation 2 ) compare ZES resolute EES 3 month ( early period ) stent implantation .</brief_summary>
	<brief_title>ComparisiOn Neointimal coVerage betwEen ZES EES Using OCT 3 Months</brief_title>
	<detailed_description>Recent autopsy study show important histological morphometric predictor stent thrombosis endothelial coverage ratio uncover total strut drug elute stent ( DES ) implantation . Although controversy , incomplete stent apposition might possible cause late stent thrombosis DES implantation . Therefore , theoretically dual antiplatelet therapy continue prevent stent thrombosis complete reendothelialization . But , detection endothelial coverage stent possible available intravascular device clinical practice . Among currently available intravascular device , intravascular optical coherence tomography ( OCT ) could give clear identification thin layer neointimal hyperplasia ( NIH ) malapposition high-resolution ( 10 -20 μm ) compare intravascular ultrasound ( 100-150 μm ) . Previous OCT study show significant different pattern neointimal coverage baremetal stent ( BMS ) DES . In experience , also differences neointimal coverage among DESs , especially zotarolimus elute stent ( ZES ) . ZES know associate significantly neointimal coverage SES 8 month intravascular untrasound ( IVUS ) . This finding might relate strut thickness drug elution property . In data , 99.7 % stent strut cover neointima ZES , 93.2 % sirolimus elute stent ( SES ) 9 month follow-up OCT . This difference distinct patient acute myocardial infarction ( 99.3 % ZES vs.79.9 % SES ) . Both everolimus eluting stent ( EES ) recently introduce ZES resolute also available near future Korea . Previous phosphorylcholine polymer replace new , proprietary polymer provide extend elution kinetics ZES resolute . Therefore , efficacy suppress neointimal growth might improve , safety neointimal coverage need evaluate human coronary artery . Both new DESs cobalt chrominum stent thin stent strut report similar efficacy suppress neointima growth . Also , endothelial coverage stent strut occur early compare previous DESs ( SES PES ) animal experiment . But , data neointimal coverage malapposition ZES resolute EES use OCT human coronary artery . Recent paper accord Kubo et al report serial OCT examination demonstrate markedly different vascular response 9 month SES implantation unstable angina stable angina patient . These finding imply initial native vessel status , cover stent , might important relate neoinitmal coverage malapposition . But , little data evaluate relationship initial lesion status neointimal coverage late malapposition OCT . Therefore , study 1 ) evaluate neointimal coverage malapposition 3 month ZES resolute EES implantation 2 ) compare ZES resolute EES 3 month stent implantation . 2 . STUDY OBJECTIVE This study prospective open label randomize study compare neointimal coverage ZES resolute ( Endeavor® resolute ) EES ( Xience® ) 3 month stent implantation OCT. 2.1 . Primary end point The primary endpoint compare pattern neointimal coverage ZES resoute ( Endeavor® resolute ) EES ( Xience® ) 3 month stent implantation OCT. 2.2 . Secondary end point The secondary objective study evaluate neointimal growth ZES resolute EES 3 month 2 ) compare difference early late malapposition ZES resolute EES 3 month . 3 . Methods Design 3.1 Patient enrollment Patients stable angina pectoris present cath lab non-emergent PCI eligible participation . A patient consider enrolled meet inclusion none exclusion criterion . Inclusion criteria - Significant coronary de novo lesion ( &gt; 70 % quantitative angiographic analysis ) - Patients stable angina pectoris consider coronary revascularization . - Reference vessel diameter 2.5 3.5 mm operator assessment Exclusion criteria The criterion exclusion - Acute coronary syndrome - Contraindication anti-platelet agent - Proximal leison within 15 mm ostium - Treated DES within 1 year vessel - Creatinine level 2.0 mg/dL ESRD - Severe hepatic dysfunction ( 3 time normal reference value ) - Pregnant woman woman potential childbearing - Complex lesion morphology ( aorto-ostial , unprotected Left main , chronic total occlusion ) - Target lesion vein graft lesion - Reference vessel &lt; 2.5 mm &gt; 4.0mm diameter visual 3.2 . Sample Size Statistical analysis Calculation sample size could do observation study . Therefore , decide enroll 40 patient 20 ZESs resolute 20 EESs consider sufficient stent strut ( 3000 stent strut group ) . Results express mean ±SD . Comparisons discrete variable make use chi-square test Fisher 's Exact Test . Student t-tests use continuous variable . Because distribution skew due small study sample , non-parametric test ( Mann-Whitney test unpaired variable Wilcoxon-signed rank test pair variable ) use . All statistical analysis perform SPSS 13.0 . ( SPSS Inc. , Chicago , IL , USA ) . A value p &lt; 0.05 consider statistically significant . 4 . STUDY PROCEDURE The cath lab follow site standard operating procedure PTCA stenting . Stent overlap allow . Treatment multiple vessel acceptable . However , information collect one study lesion per patient . Information collect record treat study vessel include angiographic , IVUS OCT parameter . The IVUS OCT study check procedure follow 3 month angiography . 4.1 . PROCEDURAL MATERIALS Endeavor ® resolute 2.75 3.5 mm All available length Drug Eluting Stent Xience ® 2.75 3.5 mm All available length 4.2 RANDOMIZATION Patients native coronary artery fulfill enrollment criterion randomize receive either ZES ( Endeavor® ) resolute EES ( Xience Promus® ) . Randomization perform 1:1 ratio ZES EES accord clinical presentation . 4.3 STENT SELECTION The vessel size determine either quantitative angiography IVUS appropriate stent size selection . 4.4 IVUS ASSESSMENT IVUS assessment perform use commercially available IVUS system ( Boston Scientific/ Scimed , Natick , MA ) . Studies record Index system ( Echoplaque 2 ; INDEC Systems Inc , Mountain View , CA ) off-line analysis . Motorized transducer pullback permit cross-sectional area measurement 1mm axial increment throughout length stent . All IVUS study perform intracoronary administration 200 µg nitroglycerin . The reference segment visually normal cross section ( large lumen least plaque burden ) within 10mm proximal distal lesion . Using software , external elastic membrane ( EEM ) CSA ( mm2 ) , lumen CSA ( mm2 ) , minimal stent cross-sectional area ( MSA ) ; identify CSA tight segment within stent , stent MLD determine . The CSA proximal distal reference segment stenotic lesion well CSA proximal distal stent edge determine . A determination percent expansion make measure MSA average reference segment CSA . Average reference segment CSA calculate [ Proximal Reference segment CSA +Distal Reference segment CSA ) /2 ] . Plaque volume calculate vessel minus stent volume . Neointimal volume calculate stent minus lumen volume , percentage ( % ) neointimal obstruction calculate neointimal volume divide stent volume . Neointimal coverage stent surface mean physical neointimal thickness obtain measure circumferential stent length cover neointimal hyperplasia ( LN ) stent perimeter ( LS ) every 1-mm cross-sectional image throughout stented segment : ( ) percentage neointimal coverage stent surface , calculate total LN divide total LS , ( b ) mean physical neointimal thickness , calculate mean neointimal area divide mean LN cross section detectable neointima . 4.5 . OCT ASSESSMENT OCT measurement make follow method : ( Takano M , et al . Evaluation Optical Coherence Tomography Neointimal Coverage Sirolimus-Eluting Stent Three Months After Implantation . Am J Cardiol 2007 ; 99 : 10331038 ) Cross-sectional OCT image analyze 1-mm interval ( every 15 frame ) . Neointimal hyperplasia ( NIH ) thickness inside stent strut measure . Stent area lumen area every image measure manual trace percent NIH area calculate percent NIH area = ( [ stent area - lumen area ] / stent area ) / 100 . Measured NIH thickness equal 0 micro meter define exposure , maximum distance &gt; 110 micro meter strut surface adjacent vessel surface ( thickness strut polymer ) define malapposition . On image stent malapposition , lumen area divide in-stent lumen area extra-stent lumen area . . Intracoronary thrombus define protrude mass beyond stent strut lumen . Bifurcation lesion major sidebranches exclude analysis . Inter- intraobserver variability assess evaluation 20 random cross- sectional image 2 independent reader reader 2 separate time point , respectively . 4.6 . Follow-Up All patient follow hospital discharge . When patient come back 3 9 month discharge due clinical follow-up , patient record update . 1 . Clinical follow-up 3 , 9 month 2 year procedure .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Significant coronary de novo lesion ( &gt; 70 % quantitative angiographic analysis ) Patients stable angina pectoris consider coronary revascularization . Reference vessel diameter 2.5 3.5 mm operator assessment Acute coronary syndrome Contraindication antiplatelet agent Proximal leison within 15 mm ostium Treated DES within 1 year vessel Creatinine level 2.0 mg/dL ESRD Severe hepatic dysfunction ( 3 time normal reference value ) Pregnant woman woman potential childbearing Complex lesion morphology ( aortoostial , unprotected Left main , chronic total occlusion ) Target lesion vein graft lesion Reference vessel &lt; 2.5 mm &gt; 4.0mm diameter visual</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Drug elute stent</keyword>
	<keyword>Tomography , optical coherence</keyword>
</DOC>